Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncogenic Transcription Factor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for JUN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | JUN (c-Jun) Recombinant Protein (Full-Length & bZIP Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for PPI and phosphorylation assays. |
View JUN Products |
| Gene Delivery | JUN Promise-ORF / Lentivirus Full-length human JUN ORF for stable cell line generation and AP-1 reporter assays. |
View JUN Products |
| Benchmark Ab | Anti-JUN Recombinant Antibody High-affinity sequence-verified positive control for Western Blot, ChIP, and IP assays. |
View JUN Products |
| Validator | JUN siRNA Set Target-specific knockdown pool for validation of target specificity and pathway downstream effects. |
View JUN Products |
| Related Target A | FOS (c-Fos) Essential heterodimerization partner for c-Jun to form the active AP-1 transcription factor complex. |
View FOS Products |
| Related Target B | MAPK8 (JNK1) Upstream kinase responsible for phosphorylating JUN at Ser63/Ser73, activating its transcriptional activity. |
View MAPK8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening (c-Jun/c-Fos) | Highly purified, natively folded bZIP domain proteins with guaranteed sequence verification. |
| Phosphorylation-dependent activity validation | Site-specific phosphorylated mutant proteins (Ser63/73 mimics) available for functional assay baselines. |
| Lack of Controls | Clinical-grade recombinant benchmark antibodies included in the portfolio. |
| False Positives in Transcription Factor assays | Sequence-validated siRNA sets included for orthogonal knockdown validation. |
Live JUN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for JUN therapeutics is intensifying, with major players shifting focus from traditional systemic kinase inhibitors to direct protein-protein interaction (PPI) disruptors and targeted protein degraders (PROTACs). As first-generation JNK inhibitors reach clinical maturity, the next wave of R&D is targeting the transcription factor interface directly to achieve superior oncogenic selectivity and bypass systemic toxicities associated with upstream MAPK pathway inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | FogPharma, Boehringer Ingelheim | Solid Tumors, Fibrotic Diseases | Biophysical Binding Assay (Need high-purity bZIP domain proteins) |
| PROTACs / Degraders | Arvinas, Kymera Therapeutics | Hematological Malignancies | Ubiquitination & Degradation Kinetics (Need sequence-verified JUN-ORF Lentivirus) |
| Peptide Therapeutics | Academic Spin-offs, Biotech Startups | Glioblastoma, Inflammatory Diseases | Heterodimerization Disruption Assay (Need functional c-Jun/c-Fos protein pairs) |